<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335827</url>
  </required_header>
  <id_info>
    <org_study_id>IRE-001</org_study_id>
    <nct_id>NCT02335827</nct_id>
  </id_info>
  <brief_title>Irreversible Electroporation(IRE) For Unresectable Renal Tumors</brief_title>
  <acronym>IRE</acronym>
  <official_title>Irreversible Electroporation (IRE) for Unresectable Renal Tumors: Phase I and Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of irreversible
      electroporation (IRE) for unresectable renal tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with renal tumors adapted to enrolled criteria, this study will
      document for the first time the safety and the short and long term efficacy of percutaneous
      or intraoperative IRE for renal tumors .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse effects</measure>
    <time_frame>1 month</time_frame>
    <description>adverse effects measured by such as abdominal bleeding, continuous abdominal pain, renal failure, et al.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>2 months</time_frame>
    <description>Quality of Life assessed as WHOQOL-BREF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>procedural compliance</measure>
    <time_frame>3 months</time_frame>
    <description>compliance will be analyzed by 3 months of follow-up post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>efficacy assessment by percentage of lesions that show no sign of recurrence 12 months after the initial IRE procedure) of IRE for renal tumor via cross-sectional imaging and pathological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voltage (A minimum and maximum range of voltage for safe and effective IRE)</measure>
    <time_frame>3 months</time_frame>
    <description>A minimum and maximum range of voltage for safe and effective IRE will be analyzed for optimal choice.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progress free disease (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Patients will be followed for 12 months after IRE for PFS assessing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Patients will be followed for 36 months after IRE for OS analyzed.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Renal Tumor</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation with voltage in level A for renal tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation with voltage in level B for renal tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation with voltage in level C for renal tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>irreversible electroporation</intervention_name>
    <description>Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unresectable kidney tumors

          -  patients refused surgical therapy

          -  Karnofsky-index &gt;70%

          -  Age ≥ 18 and ≤ 80 years

          -  life expectancy ≥ 12 month

          -  compliance of the patient taking part in a study

          -  informed consent

        Exclusion Criteria:

          -  violation against one or more inclusion criteria

          -  an estimated glomerular filtration rate (eGFR) of &lt; 30 mL/min/1.73 m2

          -  QT-interval &gt;550 ms or cardiac arrhythmias or condition after myocardial infarction,
             that make an ECG-synchronisation unfeasible

          -  active infection or severe health interference, that make taking part in a study
             unfeasible

          -  pregnancy, lactation period

          -  general contraindications for anesthesia, endotracheal anesthesia and muscle
             relaxation

          -  psychiatric disorders that make taking part in a study or giving informed consent
             unfeasible

          -  haemorrhage, impossible intermission of taking blood thinner, untreatable
             thrombophilia

          -  thromboplastin time ≤50 %, thrombocytes ≤50 Gpt/L; partial thromboplastin time &gt;50

          -  untreated urinary retention

          -  severe hepatic dysfunction

          -  any other clinically important renal, hematological, metabolic, neurological,
             gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study
             participation (investigator's assessment)

          -  taking part in another clinical study for renal tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lizhi Niu, PHD</last_name>
    <email>m18922261535@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuda Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510665</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quincy LH He, Dr.</last_name>
      <email>m18922261535@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>March 27, 2016</last_update_submitted>
  <last_update_submitted_qc>March 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irreversible electroporation</keyword>
  <keyword>renal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

